| Identification | Back Directory | [Name]
4-Piperidinamine, 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-2-quinolinyl]-N-(tetrahydro-2H-pyran-4-yl)- | [CAS]
2244614-14-8 | [Synonyms]
CYM-53093
Navacaprant
BTRX-335140
1-[6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-2-quinolyl]-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine
1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine
4-Piperidinamine, 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-2-quinolinyl]-N-(tetrahydro-2H-pyran-4-yl)-
CNS,BTRX-335140,CYM53093,U69593,Inhibitor,U2OS,Opioid Receptor,inhibit,BTRX335140,neurobehavioral disorder,CYM 53093,oral,BTRX 335140 | [Molecular Formula]
C25H32FN5O2 | [MOL File]
2244614-14-8.mol | [Molecular Weight]
453.55 |
| Chemical Properties | Back Directory | [Boiling point ]
649.8±65.0 °C(Predicted) | [density ]
1.26±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
9.04±0.20(Predicted) | [color ]
Off-white to light yellow | [InChI]
InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3 | [InChIKey]
CQOJHAJWCDJEAT-UHFFFAOYSA-N | [SMILES]
N1(C2C(C3ON=C(C)N=3)=C(C)C3C(N=2)=C(F)C=C(CC)C=3)CCC(NC2CCOCC2)CC1 |
| Hazard Information | Back Directory | [Uses]
Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC50 values of 0.8 nM, 110 nM, and 6500 nM, respectively.
Navacaprant endows with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rats. Navacaprant distributes well into the CNS and can be used for the research of neuropathy[1]. | [in vivo]
Navacaprant (BTRX-335140) (0.01-3 mg/kg; p.o. once) reduces U69,593- stimulated plasma prolactin secretion to levels of without U69,593 treatment[1].
Navacaprant (BTRX-335140) (1 mg/kg; i.p. once) blocks U-50488-induced antinociception from hot water[1].
1.19 Pharmacokinetic Parameters of BTRX-335140 in rodents[1]. | Rats
IV 1 mg/kg | Mice
IV 3 mg/kg | Rats
PO 5 mg/kg | Mice
PO 10 mg/kg | | CL (mL/min/kg) | 105 | 66.5 | | | | t1/2 (h) | 1.81 | 1.91 | 6.19 | 2.57 | | AUC0-t (h?ng/mL) | 153 | 725 | 265 | 232 | | Vss (L/kg) | 13.8 | 7.72 | | | | F (%) | | | 30.2 | 12 |
| Animal Model: | Rat PRL model[1] | | Dosage: | 0.01, 0.03, 0.1, 0.3, 1 and 3 mg/kg | | Administration: | Oral gavage; 0.01-3 mg/kg once | | Result: | Effectively decreased the high level prolactin caused by U69,593 even at a dosage of 0.1 mg/kg. |
| Animal Model: | Adult male ICR mice with tail dipped into 50°C hot water[1] | | Dosage: | 1 mg/kg | | Administration: | Intraperitoneal injection; 1 mg/kg once | | Result: | Blocked the U-50488-induced antinociception at 1 h but not at 24 h pretreatment time and showed a medication-like duration of action in blocking the KOR. |
| [IC 50]
κ Opioid Receptor/KOR: 0.8 nM (IC50); μ Opioid Receptor/MOR: 110 nM (IC50); δ Opioid Receptor/DOR: 6500 nM (IC50) | [References]
[1] Guerrero M, et al. Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140). J Med Chem. 2019 Feb 28;62(4):1761-1780. DOI:10.1021/acs.jmedchem.8b01679 |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
www.chemicalbook.com/showsupplierproductslist927327/0_en.htm |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|